Guggenheim Grand Rounds: Discussing Freenome SimpleScreen V2 Prospective Data Readout & Outlook for the Blood-Based Cancer Screening Space

Research evidence excerpt

Guggenheim Grand Rounds: Discussing Freenome SimpleScreen V2 Prospective Data Readout & Outlook for the Blood-Based Cancer Screening Space

Diagnostics & Life Sciences Tools July 20, 2026

Subbu Nambi, Ph.D.

subbu.nambi@guggenheimpartners.com Guggenheim Grand Rounds: Discussing Freenome

617 874 7383 SimpleScreen V2 Prospective Data Readout & Ricki Levitus

ricki.levitus@guggenheimpartners.com Outlook for the Blood-Based Cancer Screening

212 823 6556

Space Thomas VonDerVellen

thomas.vondervellen@guggenheimpartners.com

617 859 4657 Key Message: We hosted a grand rounds call with an expert physician in clinical

diagnostics to discuss the recent Freenome SimpleScreen V2 prospective data readout

and implications for the non-invasive CRC screening space and MCED testing

landscape. Our key conclusions are that both stage I CRC and AA detection will be Ticker Price Rating

important to physicians and patients, and personal goals and preferences may inform CAI 16.49 Buy

which is given the most importance when choosing a test. While academic debates GH 155.87 Buy will focus on assay performance, real-world test selection will be driven by commercial

GRAL 72.62 Buy and logistic considerations, especially when performance is similar. The ABT/Freenome

partnership provides Freenome with valuable commercial infrastructure and resources to

meet these needs and GH continues to build out their strong commercial infrastructure.

This call also reinforced our view that MCED tests are complementary to, rather than

competing with, non-invasive CRC screening assays today, and that Galleri remains the

MCED market leader with the most robust dataset.

Setting the Stage

What Did We Do?

We held a grand rounds call with a clinical diagnostics expert to understand their •